Alopecia

Posts

Alopecia Market Research 2018

Alopecia Market Research 2018

Alopecia Market Research 2018 with top Countries data: Region Wise Analysis of Top Players in Market by its Types and Application and Forecast to 2023

Alopecia Market provides deep understanding, clarifies varieties of the market to help you decide not only the succeeding strategy but also to achieve the desired market position. This market research is a combined result of inputs from industry experts with awareness, the experience of Alopecia market and qualitative and quantitative synthesis of the market.

Description: Alopecia is a term used to describe excessive hair damage under certain medical conditions or dietary issues.

Top key players of the industry are covered in Alopecia Market Research Report:

  • Lifes2good, Kirkland Signature, Johnson & Johnson, Dr. Reddy’s Laboratories., Cipla., Alpecin., Vitabiotics., Sun Pharma., Phyto Ales Group…

The worldwide market for Alopecia Market is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2018.

Split by product type, with production, revenue, price, market share and growth rate of each type, can be divided into:

  • Oral treatment, Topical treatment, Other treatment…

Split by application, this report focuses on consumption, market share and growth rate of Alopecia market in each application and can be divided into:

  • Male, Female

Global Alopecia Market: Regional Segment Analysis (Regional Production Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

  • North America (the USA, Canada, and Mexico)
  • Europe (Germany, France, UK, Russia, and Italy)
  • Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)
  • South America (Brazil, Argentina, Columbia, etc.)
  • The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

Target Audience of Alopecia Market:

  • Manufacturer / Potential Investors
  • Traders, Distributors, Wholesalers, Retailers, Importers, and Exporters.
  • Association and government bodies.

Alopecia Market Influencing Factors:

  • Market Environment: Government Policies, Technological Changes, Market Risks.
  • Market Drivers: Growing Demand, Reduction in Cost, Market Opportunities and Challenges.

Key questions answered in the Alopecia Market report:

  • What will the Alopecia market size and the growth rate be in 2023?
  • What are the key market trends impacting the growth of the Alopecia market?
  • Who are the global key manufacturers of Alopecia industry: Company Introduction, Product Specification, and Major Types Analysis, Production Market Performance, Sales Market Performance, Contact Information.
  • What are the types and applications of Alopecia? What is the market share of each type and application: production, revenue, price, Market Size (Sales) Market Share by Type.
  • What are the upstream raw materials and manufacturing equipment of Alopecia? Up Stream Industries Analysis, Raw Material and Suppliers, Equipment and Suppliers, Manufacturing Analysis, Manufacturing Process, Manufacturing Cost Structure, Manufacturing Plants Distribution Analysis, Industry Chain Structure Analysis
  • What is the global (North America, South America, Europe, Africa, Middle East, Asia, China, Japan) production, production value, consumption, consumption value, import and export of Alopecia?
  • What are the Alopecia market opportunities and threats faced by the vendors in the global Alopecia Industry?

Alopecia Market Research 2018 with top Countries data

Source

Global Alopecia Market Professional Survey

Global Alopecia Market Professional Survey

Global Alopecia Market Professional Survey Report 2018

Research Methodology

Global Alopecia market is anticipated to grow at a CAGR of XX% by 2023, according to a new report published by Marketintelligencedata Inc. The report segments the market and forecasts its size, by volume and value, on the basis of application, by-products, and by geography (North America, Europe, Asia-Pacific, MEA and South America).

The Global Market for Alopecia to 2023 offers detailed coverage of guanidine Alopecia industry and presents main market trends. The market research gives historical and forecast market size, demand and production forecasts, end use demand details, price trends, and company shares of the leading Alopecia producers to provide exhaustive coverage of the guanidine carbonate.

This research report includes the following contents:

  • Alopecia Product details, including pictures and technical specifications
  • Alopecia manufacturers, distributors, and channels
  • Major players present in the Alopecia
  • Information on competitor market shares, revenue, unit sales, etc
  • Breakdown by applications for the Market
  • Value chain and distributor details in the market

Key vendors:

  • Lifes2good
  • Kirkland Signature
  • Johnson & Johnson
  • Dr. Reddy’s Laboratories.
  • Cipla.
  • Alpecin.
  • Vitabiotics.
  • Sun Pharma.
  • Phyto Ales Group

Key regions:

North America, Europe, China, Japan, India, Southeast Asia, Other regions (Central & South America, Middle East & Africa)

Additionally, the market is segmented by the following sectors

  • Oral treatment
  • Topical treatment
  • Other treatment

Not only this, figures covering the end-user applications are also provided according to the following classification

  • Male
  • Female

In summary, the report serves to study and analyze the Alopecia size (value & volume) by the company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025. This report includes the estimation of market size for value (million US$) and volume (K MT). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alopecia, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares split, and breakdowns have been determined using secondary sources and verified primary sources.

Overall the report is an excellent source for managers, researches and top executives alike to analyze and get clarity on the market standings and business forecast. We provide the information after thorough research and analysis saving precious hours and budget for the companies. We have been serving major clients like Sony, BCG, PWC, Mck, Hewlett Packard, Technicolor Etc.

Global Alopecia Market Professional Survey Report 2018

Source

Alopecia Treatment Market Outlook

Alopecia Treatment Market Outlook

Alopecia Treatment Market Outlook; Development Trends, Market Demands & Forecast by 2023 Industry Key players

Alopecia Treatment Market By Disease Type (Androgenic Alopecia, Cicatricial Alopecia, Alopecia Areata, Traction Alopecia and Alopecia Totalis) By Treatment Type (Topical Drugs, Injectable, Low Level Laser Therapy, Oral Drugs and Hair Transplant Services) By End-User (Homecare Settings, Dermatology Clinics and Others)- Global Industry Analysis & Forecast to 2023

Alopecia Treatment Market: Industry Outlook and Trend Analysis

The Alopecia Treatment Market has encountered significant development in recent years and is anticipated to grow tremendously over the forecast period. Alopecia also recognized as hair-loss or baldness is a medicinal condition that alludes to the loss of hairs from the head or any part of the body. The condition can happen in both male and female and at any age.

There are five main kinds of alopecia to be specific; androgenic alopecia, cicatricial alopecia, androgenic alopecia, alopecia totalis, and traction alopecia. Development of the alopecia treatment market is fundamentally determined by expanding interest in hair loss treatment drugs with improved viability and insignificant reactions. For instance, as of late cytokine therapy too regenerative cell treatment is picking up demand for treatment of different sorts of alopecia.

Alopecia Treatment Market Competitive Insights:

The leading players in the market are Ranbaxy Laboratories, Dr. Reddy’s Laboratories, Nanogen, Merck & Co, Vitabiotics, Viviscal, Kirkland Signature, Cipla, Phyto – Alès Groupe and Johnson and Johnson. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.

Alopecia Treatment Market: Treatment Type Outlook

Topical medications incorporate lotions, gels, creams, foam, and shampoos, while the injectable treatment composes section incorporates steroids, platelet-rich plasma therapy, and injectable fillers. Propecia, an oral drug is at present the main FDA affirmed medication in the treatment of alopecia. Restricted clinical efficacy exhibited by such medicines would hamper market and income development of established products over the figure time frame.

Alopecia Treatment Market: End User Outlook

Dermatology and trichology clinics section is the most elevated income supporter of the alopecia treatment market trailed by home care settings and end-user portions. Over the counter distribution and rising level of e-Commerce, implementation is anticipated to prompt an expanded selection of topical hair loss treatments in home care settings.

Alopecia Treatment Market: Regional Outlook and Trend Analysis

North America, trailed by Europe, is foreseen to overwhelm the alopecia treatment market all through the conjecture time frame. The Asia Pacific is anticipated to witness the speediest development attributable to the upheaval of a middle-aged populace in the area. Likewise, the district is observing sound development as far as GDP, which is anticipated to move development at solid digits. The Middle East and Africa and Latin America are foreseen to encounter sluggish development amid the conjecture time frame.

Major Table of Contents:

Chapter1. Introduction

Chapter2. Executive Summary

Chapter3. Market Overview

Chapter4.Market Analysis by Regions

Chapter5. Alopecia Treatment Market, By Disease Type

Chapter6. Alopecia Treatment Market, By Treatment Type

Chapter7. Alopecia Treatment Market, By End User

Chapter8. Alopecia Treatment Market, By Region

Alopecia Treatment Market Research Methodology:

We use both primary as well as secondary research for our market surveys, estimates and for developing the forecast. Our research process commences by analyzing the problem which enables us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to the changing nature of products and markets while retaining the core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.

About Crystal Market Research:

Crystal Market Research is a U.S. based market research and business intelligence company. Crystal offers a one-stop solution for market research, business intelligence, and consulting services to help clients make more informed decisions. It provides both syndicated as well as customized research studies for its customers spread across the globe. The company offers market intelligence reports across a broad range of industries including healthcare, chemicals & materials, technology, automotive, and energy.

Alopecia Treatment Market Outlook

Source

Samumed Doses First Subject in Phase 2/3 Trial of SM04554

Samumed Doses First Subject in Phase 2/3 Trial of SM04554

Samumed Doses First Subject in Phase 2/3 Trial of SM04554 for the Treatment of Androgenetic Alopecia

Samumed, LLC, announced today that it has dosed the first subject in its phase 2/3 trial of SM04554, a topical small molecule Wnt pathway activator, for the treatment of androgenetic alopecia (AGA), the most common type of hair loss in men and women. This trial is being conducted as a pivotal study in Turkey and is expected to enroll approximately 625 patients across 11 study sites.

This study is conducted under an IND with the FDA. In addition, the Ministry of Health of Turkey has confirmed that the study, if successful, would support submission of a marketing application for SM04554 in Turkey.

“We have shown in phase 2 trials that daily treatment with SM04554 appeared safe and increased follicle counts and non-vellus hair counts compared to vehicle in males with AGA after 90 days of exposure,” said Yusuf Yazici, M.D., Chief Medical Officer of Samumed. “In order to build upon these results, this study will evaluate the effect of treatment with topical SM04554 applied daily for 48 weeks on males with AGA. We anticipate top-line results in the second half of 2020.”

This trial is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of topical SM04554 solution (0.15% & 0.25%) applied daily to the scalp of male AGA subjects. The trial is a 54-week study, with 48 weeks of treatment followed by 6 weeks of follow-up. The primary endpoint of the study is the baseline-adjusted absolute non-vellus hair count in the target area by phototrichogram analysis at Week 48 compared to vehicle.

Prof. Server Serdaroglu, M.D., principal investigator in this study, said, “The negative psychological effects of androgenetic alopecia are well documented. Currently available treatments have limited efficacy and patients need access to better options. We look forward to contributing to this important clinical study which will examine the effects of SM04554 over the course of one year.”

Samumed has completed two phase 2 studies examining the safety, tolerability, and efficacy of SM04554 for the treatment of AGA. These studies demonstrated that treatment with SM04554 appeared to be well-tolerated and safe. Key clinical results have shown that treatment with SM04554 applied daily (90 days) to the scalp resulted in:

About Androgenetic Alopecia

Androgenetic alopecia (AGA) is the most common type of hair loss in men and women, affecting an estimated 50 million men and 30 million women in the US. It is characterized by varying degrees of hair thinning that occurs as terminal (mature) hairs are gradually “miniaturized” to vellus (fine/wispy) and dormant hairs. AGA generally presents in a characteristic pattern and varies by age and race. It is most prevalent among Caucasians, with approximately half of men developing hair loss by age 50 and one-third of women developing some form of loss as age increases.

About SM04554

SM04554 is a topical small molecule Wnt pathway activator being developed for the treatment of androgenetic alopecia (AGA). Additional information on Samumed’s SM04554 AGA program can be found here: https://www.samumed.com/pipeline/detail.aspx?id=16

About Samumed

Samumed’s small-molecule drug platform is harnessing the innate restorative power of the Wnt pathway to reverse the course of severe and prevalent diseases.

Learn more about Samumed’s potential regenerative drug candidates and broad clinical pipeline at: https://www.samumed.com/pipeline/default.aspx

Samumed Doses First Subject in Phase 2/3 Trial of SM04554 for the Treatment of Androgenetic Alopecia

Source

Global Alopecia Drugs Market Insights Forecast to 2025

Global Alopecia Drugs Market Insights Forecast to 2025

Global Alopecia Drugs Market Insights Forecast to 2025

This report studies the global market size of Alopecia Drugs in key regions like North America, Europe, Asia Pacific, Central & South America, and the Middle East & Africa focuses on the consumption of Alopecia Drugs in these regions.

This research report categorizes the global Alopecia Drugs market by players/brands, region, type, and application. This report also studies the global market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels, distributors and Porter’s Five Forces Analysis.

Alopecia drugs are being used for unapproved clinical indication or extension to a milder form of approved indication or extension to related conditions. For instance, alopecia market heavily uses spironolactone and cyclosporine, which are primarily approved for other indications.

The global topical drugs market segment accounted for the maximum market share during 2017 and will continue to dominate the market until the end of 2025. Topical drugs are widely used in comparison to oral formulations. The increasing availability and popularity of new drugs, such as the AVODART drug, will fuel the growth prospects for the market during the forecast period.

In 2017, the global Alopecia Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018. The objectives of this study are to define, segment, and project the size of the Alopecia Drugs market based on company, product type, application and key regions.

The various contributors involved in the value chain of Alopecia Drugs include manufacturers, suppliers, distributors, intermediaries, and customers. The key manufacturers in the Alopecia Drugs include

GlaxoSmithKline
Johnson & Johnson
Merck
Aclaris Therapeutics
Polichem
Promius Pharma
Ranbaxy Laboratories
Reckitt Benckiser
Regience
Samumed
RepliCel
Skinvisible Pharmaceuticals
Teva Pharmaceutical
Market Size Split by Type
Oral Alopecia Drugs
Topical Alopecia Drugs
Injectable Alopecia Drugs
Market Size Split by Application
Hospitals
Specialty Clinics
Market size split by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:

To study and analyze the global Alopecia Drugs market size (value & volume) by the company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025.

To understand the structure of Alopecia Drugs market by identifying its various sub-segments.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

Focuses on the key global Alopecia Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in the next few years.

To analyze the Alopecia Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.

To project the value and volume of Alopecia Drugs submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Alopecia Drugs are as follows:

History Year: 2013-2017

Base Year: 2017

Estimated Year: 2018

Forecast Year 2018 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alopecia Drugs market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Global Alopecia Drugs Market Insights Forecast to 2025

Source

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis

Dupilumab is an interleukin (IL)-4 receptor alpha antagonist that was approved by the US Food and Drug Administration in March 2017 for the treatment of adult patients with moderate to severe atopic dermatitis not adequately controlled with topical therapies.

In addition to effectively treating a resistant case of atopic dermatitis, the eczema drug dupilumab (Dupixent, Regeneron Pharmaceutics) triggered hair growth in a young patient with longstanding alopecia totalis, investigators report.

The dual efficacy of the interleukin (IL)-4 receptor alpha antagonist, which was approved by the US Food and Drug Administration in March 2017 for the treatment of moderate to severe atopic dermatitis, may be explained by the immune characteristics shared by both conditions, Lauren R. Penzi, MD, from the Department of Dermatology, Massachusetts General Hospital, Boston, and colleagues write in a case report published online October 10 in JAMA Dermatology.

Atopic dermatitis is a TH2-mediated disease with elevated IL-4, IL-5, IL-13, and IL-31, and although the pathogenesis of alopecia totalis — an advanced form of alopecia areata — is not fully understood, recent studies point to a strong TH2 link as well, the authors write. Dupilumab improves eczema symptoms by blocking the signaling of IL-4 and IL-13 cytokines, which play a role in maintaining the immune response of TH2 cells.

The case report describes the treatment of a 13-year-old girl with a history of treatment-resistant atopic dermatitis since age 7 months and atopic totalis since age 2 years. Previous treatment for alopecia totalis with topical squaric acid and anthralin was not effective. Trial treatment for both conditions with pulsed prednisone and methotrexate led to some improvement in the dermatitis, but not the alopecia, and thus was discontinued, and topical steroid treatment for the dermatitis did not produce an adequate response.

The patient began weekly injections of dupilumab in 2017. After 6 weeks of treatment her eczema improved significantly and vellus hairs began growing on her scalp. “Nine months after beginning dupilumab treatment, the patient had grown pigmented, terminal hairs on approximately 60% of the scalp,” the authors write.

During an unplanned 2-month treatment hiatus related to insurance coverage, the patient reported hair shedding, which resolved when treatment was restarted. “At last follow-up, 11 months after the first dupilumab dose, considerable hair growth was noted,” the authors write.

The patient reported minimal dry eye, a side effect that has been reported previously with dupilumab treatment, as have other adverse reactions including injection-site reactions, conjunctivitis, blepharitis, oral herpes, keratitis, eye pruritus, and other herpes simplex virus infection, the authors explain. “There have been no reports to our knowledge of hair growth in alopecia areata related to dupilumab,” they note.

“Right now, it’s hard to know whether dupilumab could induce hair growth in other alopecia patients, but I suspect it may be helpful in patients with extensive active eczema and active alopecia areata,” senior author Maryanne Makredes Senna, MD, from the Department of Dermatology, Massachusetts General Hospital, Boston, said in a hospital news release.

Another possible explanation for the observed improvement in the patient’s alopecia, according to Amy McMichael, MD, professor and chair, Department of Dermatology at Wake Forest Baptist Medical Center in Winston-Salem, North Carolina, “might be that the eczema was so severe on the scalp that there was another form of hair loss called telogen effluvium taking place in addition to the alopecia areata.”

Telogen effluvium is a nonscarring, shedding form of hair loss that often occurs when there is an inflammatory insult to the scalp, McMichael told Medscape Medical News. “Once the dupilumab was able to clear the eczema, this may have ended the telogen effluvium, leaving only the remaining alopecia areata, possibly accounting for why there is still partial hair regrowth.”
It is too early to tell whether dupilumab could trigger hair regrowth in other patients with alopecia totalis or individuals with other types of hair loss. “We first need to clarify what kind of hair loss we are really discussing, since there are many forms. The form discussed by the authors, alopecia areata, [is] an autoimmune form of hair loss that is seen more commonly in those younger than age 40, but can occur in anyone of any age,” McMichael explained.

“As noted, this form of hair loss is mediated by white blood cells that have certain markers identifying them as TH2 cells, and atopic dermatitis is known to be mediated by these same kinds of cells, though the mechanism of each is very complex and differ in many ways.” As both disorders are often seen in the same patients, “the idea that a single treatment might work for both is not completely out of the realm of possibility and has been observed with other biologic medications in the past,” she added.

Clinical trials testing the whether dupilumab might improve alopecia areata are warranted, McMichael stressed, noting also that additional preclinical studies “may offer even more insight to the mechanism of this eczema drug on alopecia areata.”

The investigators report that they have submitted a proposal for a clinical trial of dupilumab in patients with extensive active eczema and active alopecia areata.

Eczema Drug Dupilumab Spurs Hair Regrowth in Alopecia Totalis

Source

 

Global and Chinese Alopecia Industry 2018 Market Research

Global and Chinese Alopecia Industry 2018 Market Research

Global and Chinese Alopecia Industry 2018 Market Research report

The ‘Global and Chinese Alopecia Industry, 2013-2023 Market Research Report’ is a professional and in-depth study on the current state of the global Alopecia industry with a focus on the Chinese market.

The report provides key statistics on the market status of the Alopecia manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

Firstly, the report provides a basic overview of the industry including its definition, applications and manufacturing technology. Then, the report explores the international and Chinese major industry players in detail. In this part, the report presents the company profile, product specifications, capacity, production value, and 2013-2018 market shares for each company.

Through the statistical analysis, the report depicts the global and Chinese total market of Alopecia industry including capacity, production, production value, cost/profit, supply/demand and Chinese import/export.

The total market is further divided by company, by country, and by application/type for the competitive landscape analysis. The report then estimates 2018-2023 market development trends of Alopecia industry.

Analysis of upstream raw materials, downstream demand and current market dynamics is also carried out. In the end, the report makes some important proposals for a new project of Alopecia Industry before evaluating its feasibility.

Overall, the report provides an in-depth insight of 2013-2023 global and Chinese Alopecia industry covering all important parameters.

TOC of Global and Chinese Alopecia Industry, 2018 Market Research Report

Chapter One Introduction of Alopecia Industry

Chapter Two Manufacturing Technology of Alopecia

Chapter Three Analysis of Global Key Manufacturers

Chapter Four 2013-2018 Global and Chinese Market of Alopecia

Chapter Five Market Status of Alopecia Industry

Chapter Six 2018-2023 Market Forecast of Global and Chinese Alopecia Industry

Chapter Seven Analysis of Alopecia Industry Chain

Chapter Eight Global and Chinese Economic Impact on Alopecia Industry

Chapter Nine Market Dynamics of Alopecia Industry

Chapter Ten Proposals for New Project

Chapter Eleven Research Conclusions of Global and Chinese Alopecia Industry

Global and Chinese Alopecia Industry 2018 Market Research report

Source

Global Alopecia Market Insights, Forecast to 2025

Global Alopecia Market Insights, Forecast to 2025

Global Alopecia Market Insights, Forecast to 2025

Global Alopecia (Hair Loss Treatment) market is anticipated to grow at a CAGR of XX% by 2023, according to a new report published by ResearchVector Inc.

The report segments the market and forecasts its size, by volume and value, on the basis of application, by-products, and by geography (North America, Europe, Asia-Pacific, MEA and South America).

The Global Market for Alopecia (Hair Loss Treatment) to 2023 offers detailed coverage of guanidine Alopecia (Hair Loss Treatment) industry and presents main market trends. The market research gives historical and forecast market size, demand, and production forecasts, end use demand details, price trends, and company shares of the leading Alopecia (Hair Loss Treatment) producers to provide exhaustive coverage of the guanidine carbonate.

This research report includes the following contents:

  • Alopecia (Hair Loss Treatment) Product details, including pictures and technical specifications
  • Alopecia (Hair Loss Treatment) manufacturers, distributors and channels
  • Major players present in the Alopecia (Hair Loss Treatment)
  • Information on competitor market shares, revenue, unit sales etc
  • Breakdown by applications for the Market
  • Value chain and distributor details in the market

Key vendors:

  • Shiseido
  • Rohto
  • Unilever
  • Taisho
  • Angfa
  • LOreal
  • Kaminomoto
  • Merck
  • Yanagiya Honten
  • Amorepacific
  • Procter & Gamble
  • Himalaya
  • Gerolymatos International
  • Merz Pharma
  • Leader Teck
  • Vasu Healthcare
  • VLCC
  • Ales Group
  • Shanxi Ante
  • Wansheng Pharmaceutical
  • Advanced Skin and Hair
  • Humanwell Healthcare
  • Topfond
  • Lifes2good
  • Bawang
  • YNK Pharmaceutical
  • Apollo
  • Jingxiutang
  • Rogaine
  • Marico

Key regions:

United States, Canada, Mexico, China, India, Japan, South Korea, Australia, Indonesia, Singapore, Malaysia, Philippines, Thailand, Vietnam, Germany, France, UK, Italy, Spain, Russia, Brazil, Rest of Central & South America, GCC Countries, Turkey, Egypt, South Africa

Additionally, the market is segmented by the following sectors

  • Shampoos and Conditioners
  • Medicine Product

Not only this, but figures covering the end-user applications are also provided according to the following classification

  • Men
  • Women

In summary, the report serves to study and analyse the Alopecia (Hair Loss Treatment) size (value & volume) by the company, key regions/countries, products and application, history data from 2013 to 2017, and forecast to 2025. This report includes the estimation of market size for value (million US$) and volume (K MT).

Both top-down and bottom-up approaches have been used to estimate and validate the market size of Alopecia (Hair Loss Treatment), to estimate the size of various other dependent submarkets in the overall market.

Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares split, and breakdowns have been determined using secondary sources and verified primary sources.

Overall the report is an excellent source for managers, researches and top executives alike to analyse and get clarity on the market standings and business forecast. We provide the information after thorough research and analysis saving precious hours and budget for the companies. We have been serving major clients like Sony, BCG, PWC, Mck, Hewlett Packard, Technicolor Etc.

Number of Pages 148

Published Date12 September 2018

Single User Price $3900.0

Enterprise User Price$7800.0

Global Alopecia Market Insights, Forecast to 2025

Source

Breakthrough Therapy for Alopecia Areata

Breakthrough Therapy for Alopecia Areata

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600, an oral JAK3 Inhibitor, for the Treatment of Patients with Alopecia Areata

Phase II data accepted for late-breaker news session at 2018 EADV Congress

“Pfizer strives to continue moving the JAK science forward with development of multiple JAKis with unique selectivity profiles that are being evaluated in clinical trials. These inhibitors have the potential of meeting significant unmet needs in multiple inflammatory conditions”

Pfizer Inc today announced its investigational oral Janus kinase 3 (JAK3) inhibitor PF-06651600 received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of patients with alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face, or body.

The Breakthrough Therapy designation for alopecia areata was supported by positive results from a Phase 2 study, which will be presented during the late-breaking news session at the 27th European Academy of Dermatology and Venerology (EADV) Congress in Paris on September 15, 2018. Currently, there are no FDA-approved treatments for alopecia areata, which impacts millions of people worldwide and is often associated with profound psychological consequences.

“We are encouraged by this Breakthrough Therapy designation as it underscores the potential of our JAK3 inhibitor to address a critical unmet need,” said Michael Corbo, Chief Development Officer, Inflammation & Immunology, Pfizer Global Product Development. “We are continuing to work closely with the FDA on the development process with the goal of bringing this potential new treatment to patients living with alopecia areata as soon as possible.”

Breakthrough Therapy designation was initiated as part of the Food and Drug Administration Safety and Innovation Act (FDASIA) signed in 2012. As defined by the FDA, a Breakthrough Therapy is a drug intended to be used alone or in combination with one or more other drugs to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as a Breakthrough Therapy, the FDA will expedite the development and review of such drug.

Pfizer is also working with the European Medicines Agency (EMA) on the clinical development program for PF-06651600.

About Alopecia Areata

Alopecia areata is an autoimmune disease, characterized by hair loss, often patchy, on the scalp, face, or body.

People suffering from alopecia areata experience symptoms when immune cells attack healthy hair follicles, causing the hair to fall out, often starting with smooth, round patches. The mean age of onset is between 25 and 35, but it can also impact children and adolescents and is seen in both sexes and all ethnicities.

More than half of patients with alopecia areata experience a poor health-related quality of life and, as a result, the condition may lead to serious psychological consequences, including high levels of depression and anxiety.

Pfizer Receives Breakthrough Therapy Designation from FDA for PF-06651600

Source

Global Alopecia Drugs Market Insights Report

Global Alopecia Drugs Market Insights Report

Global Alopecia Drugs Market Insights Report By Product Manufacturers, Regions, Types, Sales and Applications 2018-2025: Global QYResearch

The new research from Global QYResearch on Global Alopecia Drugs Market Report for 2018 intends to offer target audience with the fresh outlook on market and fill in the knowledge gaps with the help of processed information and opinions from industry experts.

The information in the research report is well-processed and a report is accumulated by industry professionals and seasoned experts in the field to ensure the quality of research.

The research is backed by extensive and in-depth secondary research which involves reference to various statistical databases, national government documents, relevant patent and regulatory databases, news articles, press releases, company annual reports, webcasts, financial reports, and a number of internal and external proprietary databases. This estimated data is cross-checked with industry experts from various leading companies in the market.

After the entire authentication process, these reports are shared with subject matter experts (SMEs) for adding further value and to gain their insightful opinion on the research. With such a robust process of data extraction, verification, and finalization, we firmly endorse the quality of our research. With such extensive and in-depth research and comprehensive coverage of information, it is always a possibility of clients finding their desired information in the report with an enclosure of key components and valuable statistics in all regards.

Download Sample Report Copy From Here: http://globalqyresearch.com

In 2017, the global Alopecia Drugs market size was xx million US$ and is forecast to xx million US in 2025, growing at a CAGR of xx% from 2018.

The objectives of this study are to define, segment, and project the size of the Alopecia Drugs market based on company, product type, application and key regions.

The various contributors involved in the value chain of Alopecia Drugs include manufacturers, suppliers, distributors, intermediaries, and customers.

The key manufacturers of the Alopecia Drugs include

GlaxoSmithKline
Johnson & Johnson
Merck
Aclaris Therapeutics
Polichem
Promius Pharma
Ranbaxy Laboratories
Reckitt Benckiser
Regience
Samumed
RepliCel
Skinvisible Pharmaceuticals
Teva Pharmaceutical

Market Size Split by Type

Oral Alopecia Drugs
Topical Alopecia Drugs
Injectable Alopecia Drugs
Market Size Split by Application
Hospitals
Specialty Clinics

Market size split by Region

North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

About Us:

Global QYResearch is the one spot destination for all your research needs. Global QYResearch holds the repository of quality research reports from numerous publishers across the globe. Our inventory of research reports cater to various industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc.

With the complete information about the publishers and the industries they cater to for developing market research reports, we help our clients in making a purchase decision by understanding their requirements and suggesting best possible collection matching their needs.

Global Alopecia Drugs Market Insights Report

Source